Squarepoint Ops LLC Igm Biosciences, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$8.86 - $14.0 $233,124 - $368,368	26,312 New	26,312 $242,000
Q2 2022 Aug 15, 2022	SELL	$13.27 - $25.5 $475,172 - $913,104	-35,808 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$13.42 - $29.73 $356,207 - $789,123	26,543 Added 286.49%	35,808 $957,000
Q4 2021 Feb 14, 2022	BUY	$27.59 - $66.39 $255,621 - $615,103	9,265 New	9,265 $272,000
Q2 2021 Aug 16, 2021	SELL	$57.98 - $96.6 $905,879 - $1.51 Million	-15,624 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$71.56 - $121.23 $365,170 - $618,636	5,103 Added 48.5%	15,624 $1.2 Million
Q4 2020 Feb 16, 2021	BUY	$47.41 - $115.03 $359,320 - $871,812	7,579 Added 257.61%	10,521 $929,000
Q3 2020 Nov 16, 2020	SELL	$43.0 - $84.01 $581,145 - $1.14 Million	-13,515 Reduced 82.12%	2,942 $217,000
Q2 2020 Aug 14, 2020	BUY	$51.3 - $75.21 $844,244 - $1.24 Million	16,457 New	16,457 $1.2 Million
Q1 2020 May 15, 2020	SELL	$31.51 - $73.75 $585,298 - $1.37 Million	-18,575 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.25 - $49.51 $320,418 - $919,648	18,575 New	18,575 $709,000

21.4M

39.5K

16.5K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $500M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.